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BACKGROUND: Peripheral artery disease (PAD) and coronary artery disease (CAD) represent atherosclerosis in different vascu-
lar beds. We used detailed metabolic biomarker profiling to identify common and discordant biomarkers and clarify patho-
physiological differences for these vascular diseases.
METHODS AND RESULTS: We used 5 prospective cohorts from Finnish population (FINRISK 1997, 2002, 2007, and 2012, and 
Health 2000; n=31 657; median follow- up time of 14 years) to estimate associations between >200 metabolic biomarkers and 
incident PAD and CAD. Metabolic biomarkers were measured with nuclear magnetic resonance, and disease events were 
obtained from nationwide hospital records. During the follow- up, 498 incident PAD and 2073 incident CAD events occurred. 
In age- and sex- adjusted Cox models, apolipoproteins and cholesterol measures were robustly associated with incident CAD 
(eg, hazard ratio [HR] per SD for higher apolipoprotein B/A- 1 ratio, 1.30; 95% CI, 1.25– 1.36), but not with incident PAD (HR 
per SD for higher apolipoprotein B/A- 1 ratio, 1.04; 95% CI, 0.95– 1.14; Pheterogeneity<0.001). In contrast, triglyceride levels in low- 
density lipoprotein and high- density lipoprotein were associated with both end points (Pheterogeneity>0.05). Lower proportion of 
polyunsaturated fatty acids relative to total fatty acids, and higher concentrations of monounsaturated fatty acids, glycolysis- 
related metabolites, and inflammatory protein markers were strongly associated with incident PAD, and many of these as-
sociations were stronger for PAD than for CAD (Pheterogeneity<0.001). Most differences in metabolic profiles for PAD and CAD 
remained when adjusting for traditional risk factors.
CONCLUSIONS: The metabolic biomarker profile for future PAD risk is distinct from that of CAD. This may represent pathophysi-
ological differences.
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Peripheral artery disease (PAD) is a common ath-erosclerotic disease affecting body extremities. It can lead to serious complications, including 
limb ischemia and amputation, and is predictive of fu-
ture stroke and myocardial infarction.1 Atherosclerosis 
is underpinning the pathogenesis in cardiovascular 
diseases, but studies suggest that PAD risk factors 
are partly different from cerebrovascular and coronary 
artery disease (CAD).1– 4 For example, smoking and 
diabetes appear to be stronger risk factors, whereas 
hypertension and dyslipidemia are more modest for 
PAD compared with CAD.1– 3 Recent genome- wide 
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association studies have identified partly distinct ge-
netic signals for PAD compared with CAD.4 Thus, un-
covering precise metabolic pathways underlying PAD 
is required to better understand the disease pathology 
and to improve treatment.
Large prospective studies have demonstrated the 
utility of detailed metabolic profiling (also known as me-
tabolomics) in uncovering biomarkers for cardiovascular 
event risk5– 7 and elucidating the molecular pathophysi-
ology,8 which might lead to discovery of new therapeu-
tic targets. The overall pattern of metabolic biomarker 
associations with a given outcome may also help to 
dissect similarities and differences between various risk 
factors9,10 or diseases.7 This concept was recently used 
to demonstrate coherent metabolic signatures for future 
myocardial infarction and ischemic stroke risk, whereas 
the metabolic signature for intracerebral hemorrhage 
risk was found to be partly distinct.7 Only a few studies 
have examined biomarker associations with future PAD 
risk because it requires a large sample size to achieve 
sufficient end points.11 Recently, Aday et al12 used ad-
vanced lipoprotein testing in the WHS (Women’s Health 
Study) to identify different association patterns for PAD 
compared with a composite measure of cardiovascular 
and cerebrovascular disease, and suggested that pri-
mary prevention of PAD should go beyond low- density 
lipoprotein (LDL) cholesterol lowering. However, these 
findings were based on a single cohort of female health 
professionals and had modest numbers of incident 
events. Also, as nonlipid pathways seem to play more 
important roles in PAD pathophysiological features 
compared with other vascular end points, it is essen-
tial to study such biomarkers in greater detail to fur-
ther characterize these associations. Metabolic profiling 
studies have shown that several amino acids and fatty 
acids are associated with future CAD and stroke risk 
more strongly than routine lipids,5– 7 but the associa-
tions with PAD risk have yet to be evaluated.
In this study, we aimed to characterize the detailed 
lipoprotein and metabolite profile for PAD in large pro-
spective cohorts of the general population and com-
pare the results with metabolic biomarker pattern for 
future CAD events.
METHODS
The data are available for purposes of reproducing 
the results and additional research via application to 
the Finnish Institute for Health and Welfare Biobank 
(https://thl.fi/en/web/thl- biobank).
Study Populations
This observational study examined lipid and metabo-
lite associations with incident PAD and CAD events in 
5 population- based cohorts conducted by the Finnish 
Institute for Health and Welfare: the FINRISK 1997, 2002, 
2007, and 2012 cohorts, and the Health 2000 Study. 
The cohort studies were approved by the Coordinating 
Ethical Committee of the Helsinki and Uusimaa 
Hospital District, Finland. Written informed consent 
was obtained from all participants. The field surveys 
for the FINRISK cohort studies have been conducted 
every 5 years since 1972 in Finland.13 The cohorts in-
cluded in the present study were initiated in 1997, 2002, 
2007, and 2012. Health 2000 was conducted during 
2000 to 2001. Each cohort study is an independent 
random sample drawn from people aged 25 to 98 
years (25– 74 years in FINRISK and ≥30 years in Health 
2000) in the Finnish population. Participation rates to 
these cohorts have been between 60% and 70%. The 
study participants are unique in each cohort. The data 
were collected by self- administered questionnaires and 
CLINICAL PERSPECTIVE
What Is New
• Blood biomarkers for future risk of peripheral 
artery disease differ from biomarkers for risk of 
coronary artery disease in large general popula-
tion cohorts from Finland.
• Low- density lipoprotein and high- density lipo-
protein cholesterol, as well as apolipoprotein B 
and A- 1, did not associate with future hospital 
diagnosis of peripheral artery disease.
• Novel biomarkers, measured by nuclear mag-
netic resonance spectroscopy, including low- 
density lipoprotein triglycerides, serum fatty 
acids levels, and inflammatory protein mark-
ers, were strong predictors for future peripheral 
 artery disease.
What Are the Clinical Implications?
• The distinct biomarker profiles for risk of periph-
eral artery disease and coronary artery disease 
suggest pathophysiology differences for these 
2 types of atherosclerotic disease.
• Standard cholesterol measures and apolipo-
proteins are not good indicators for future risk 
of peripheral artery disease.
• Newer means to capture broader panels of 
blood biomarkers may potentially improve risk 
assessment for peripheral artery disease and 
suggest novel targets for therapies.
Nonstandard Abbreviations and Acronyms
GlycA glycoprotein acetyls
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basic risk factor assessments (including weight, height, 
and blood pressure) in each survey. Baseline blood 
samples were collected for ≈85% of all participants 
enrolled. Lipid and metabolite biomarker profiling by 
nuclear magnetic resonance (NMR) metabolomics was 
conducted from frozen serum samples for all partici-
pants in each of the cohorts. All study participants have 
been followed up using nationwide electronic health 
registries, including national hospital discharge regis-
ter, causes- of- death register, and drug reimbursement 
register. Information on use of lipid- lowering medica-
tion and blood pressure treatment was obtained from 
self- reports and the drug reimbursement register. 
Follow- up has been completed until the end of 2016. 
All study participants with available lipid and metabolite 
biomarker data were included in the present study, with 
the exception of pregnant women and individuals with 
baseline cardiovascular disease.
Disease Outcome Definitions
Disease outcomes were derived from national elec-
tronic health registries, which cover all cardiovascu-
lar events that have led to hospitalization or death in 
Finland. The cardiovascular diagnoses in these regis-
ters have been validated.14– 16 PAD was defined as the 
first occurrence of atherosclerosis of native arteries 
of the extremities, peripheral vascular operations, un-
specified PAD, and diabetes with circulatory compli-
cations (International Classification of Diseases, Tenth 
Revision [ICD- 10] codes: E10.5, E11.5, E12.5, E13.5, 
E14.5, I70.2, and I73.9). CAD was defined as the first 
occurrence of CAD event during the follow- up, com-
prising fatal or nonfatal myocardial infarction, cardiac 
revascularization (coronary artery bypass graft surgery 
or percutaneous transluminal coronary angioplasty), or 
unstable angina (codes: I21– I25, I46, R96, and R98). 
To focus on biomarkers for incident disease, individu-
als with CAD, PAD, or stroke at baseline, according 
to the registry data, were excluded from all analyses. 
Follow- up time was censored at the time of first car-
diovascular (ie, PAD or CAD) event, and subsequent 
events were not included in the analysis.
Lipid and Metabolite Biomarker Profiling
Venous blood was drawn from nonfasting samples, but 
with recommended minimum of 4- hour fast (median re-
corded fasting, 5 hours; interquartile range, 4– 6 hours). 
The samples were collected and centrifuged at the 
field survey sites and then transported to the quality- 
controlled central laboratory, where the serum samples 
have been stored in −70 °C or colder.13 Lipid and me-
tabolite measures were quantified by high- throughput 
NMR metabolomics (Nightingale Health Plc, Helsinki, 
Finland; biomarker quantification version 2020) using 
350 µL aliquots of serum. This NMR platform provides 
simultaneous quantification of routine lipids, lipoprotein 
subclass profiling with lipid concentrations within 14 
subclasses, fatty acid composition, and various low- 
molecular- weight metabolites, including amino acids, 
ketone bodies, and gluconeogenesis- related metabo-
lites, in molar concentration units. Biomarkers were 
quantified independently for each serum sample without 
using information from other samples in same well plate 
or same cohort. The average success rate of metabolite 
quantification was 99%. Technological details and epi-
demiological applications of the Nightingale NMR plat-
form have been reviewed previously.17,18 The process of 
this NMR metabolomics technology has received reg-
ulatory approval (CE), and 37 biomarkers in the panel 
have been certified for diagnostics use. Figure  S1 il-
lustrates the consistency of biomarkers measured by 
both clinical chemistry assays (conducted soon after 
sample collection) and Nightingale NMR (conducted 
from samples stored 6– 15 years before NMR measure-
ments), with correlation coefficients in line with earlier 
reports.7,17,19 To facilitate visualization, we display results 
for 57 measures spanning most of the metabolic path-
ways in the main text; complete results for all the 250 
measures quantified by the Nightingale NMR platform 
are reported in Table S1.
Statistical Analysis
All metabolic markers were scaled to SD units to en-
able comparison of biomarker associations for meas-
ures with different units and across wide concentration 
ranges. Results in absolute concentrations are re-
ported in Table S1. No transformation of the metabolite 
concentrations was used.
We used Cox proportional hazard modeling to es-
timate associations between biomarkers and incident 
PAD and CAD separately in each cohort. Hazard ra-
tios (HRs) from each cohort were meta- analyzed using 
inverse- variance weighted fixed- effect models. We 
used 2 different sets of covariates: our primary anal-
ysis was conducted adjusting for sex and age, using 
age as the time scale (model 1). In secondary analyses, 
we additionally adjusted for systolic blood pressure, 
blood pressure treatment, body mass index, prevalent 
diabetes, smoking (current versus nonsmoker), and 
lipid- lowering medication (model 2). Differences in as-
sociation magnitude for incident PAD and CAD were 







and the corresponding P value for heterogeneity de-
rived from the normal distribution. The overall con-
cordance of the biomarker association pattern with 
incident PAD and CAD was summarized using the 
linear fit of the HRs.7,20 We also conducted sensitivity 
analyses, excluding all individuals with prevalent dia-
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To account for multiple testing, we used a threshold of 
P<0.05/(50×2)=0.0005 for statistical significance, which 
is based on 50 independent tests in the NMR metabo-
lomics data (number of principal components explain-
ing 99% of variation) and 2 disease outcomes studied. 
Statistical analyses were conducted using R version 3.6 
(R Foundation for Statistical Computing, Vienna, Austria) 
and plots made using the ggforestplot package.
RESULTS
The present study included 31  657 participants from 
5 general population cohorts in Finland, all free from 
cardiovascular disease at baseline and with NMR me-
tabolomics measurements available. Baseline charac-
teristics of the study participants from each cohort are 
shown in the Table. During follow- up (median, 14 years; 
Figure 1. Apolipoprotein (Apo) and lipid associations with incident coronary artery disease (CAD) (2073 
incident events; red) and peripheral artery disease (PAD) (498 incident events; dark blue).
Hazard ratios (HRs) and 95% CIs are shown per 1- SD higher biomarker concentration, with numerical 
results indicated on the right- hand side. Models are adjusted for sex and age. Results are meta- analyzed 
for 31 657 individuals from 5 prospective cohorts. Open circles denote P≥0.0005, and closed circles 
denote P<0.0005. Asterisks denote P<0.001 for heterogeneity between PAD and CAD associations. 
Complete numerical results in absolute concentrations and SD- scaled units are listed in Table S1. Clinical 
low- density lipoprotein (LDL) cholesterol (C) and size- specific LDL- C refer to different methods for 
defining LDL.21 HDL indicates high- density lipoprotein; IDL, intermediate- density lipoprotein; P- het, P 
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interquartile range, 9– 15 years; 370 000 person- years in 
total), 498 incident PAD events and 2073 CAD events oc-
curred as the first atherosclerotic event. The median age 
of the first event was 70 years for both CAD and PAD.
Apolipoproteins and Lipids
To best enable comparison of pathophysiological dif-
ferences in biomarker patterns for PAD and CAD, the 
Figure 2. Lipoprotein subclass associations with incident coronary artery disease (CAD) (2073 
incident events; red) and peripheral artery disease (PAD) (498 incident events; dark blue).
Hazard ratios (HRs) and 95% CIs are shown per 1- SD higher biomarker concentration, with numerical 
results indicated on the right- hand side. Models are adjusted for sex and age. Open circles denote 
P≥0.0005, and closed circles denote P<0.0005. Asterisks denote P<0.001 for heterogeneity between 
PAD and CAD associations. Average particle sizes of the 14 lipoprotein subclasses (from XXL VLDL to 
S HDL) are defined in Reference 18. HDL indicates high- density lipoprotein; IDL, intermediate- density 
lipoprotein; LDL, low- density lipoprotein; P, particle concentration; P- het, P value for heterogeneity; and 
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primary results are reported with adjustment for age and 
sex only. As expected, apolipoproteins and cholesterol 
measures were robustly associated with incident CAD 
events. However, the effects were weak for incident 
PAD, with HRs close to unity (Figure 1). For example, 
higher ratio of apolipoprotein B/apolipoprotein A- 1 was 
associated with increased risk for CAD (HR, 1.30 per 1 
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1 SD; 95% CI, 0.95– 1.14; Pheterogeneity<0.001). Similar 
results were observed for apolipoprotein B and LDL 
cholesterol measures. However, higher concentrations 
of triglycerides in very- low- density lipoprotein, LDL, 
and high- density lipoprotein (HDL) were consistently 
associated with increased risk for both CAD and PAD 
(Pheterogeneity>0.05).
Lipoprotein Subclasses and Particle Size
Figure  2 shows the associations of particle concen-
trations in 14 lipoprotein subclasses and particle size 
measures with incident CAD and PAD. For particle 
concentrations, only increased concentrations of 
very- low- density lipoprotein particles were robustly 
associated with higher risk for PAD, whereas the as-
sociations for LDL and HDL subclasses were gener-
ally weak for PAD. In contrast, almost all lipoprotein 
particle concentrations were robustly associated with 
CAD, with the strongest direct associations observed 
for medium very- low- density lipoprotein (1.24; 95% CI, 
1.20– 1.29) and medium LDL (1.26; 95% CI, 1.21– 1.31; 
Pheterogeneity<0.001 with PAD association). Also, large 
HDL particles were inversely associated with incident 
CAD, but not with PAD (Pheterogeneity<0.001). Results for 
specific lipid types within the 14 lipoprotein subclasses 
broadly followed the same pattern as illustrated for 
particle concentrations (Figure S2). For the measures 
of particle size, larger very- low- density lipoprotein par-
ticle size was associated with higher risk for incident 
CAD. Larger LDL particle size was associated with 
lower risk for both end points, whereas larger HDL 
particle size was robustly associated with lower risk for 
CAD only (Pheterogeneity<0.001).
Fatty Acids, Polar Metabolites, and 
Inflammatory Proteins
In addition to lipoprotein and lipid measures, the 
Nightingale NMR platform simultaneously quan-
tifies several fatty acids, polar metabolites, and 
2 inflammatory protein measures. Many of these 
nontraditional biomarkers showed strong associa-
tions with both CAD and PAD events (Figure 3). The 
novel biomarkers tended to be particularly strong 
for PAD, with 11 of the measures having HRs >1.2 
or <0.8 per 1 SD. For comparison, the HR for body 
mass index is 1.15 (95% CI, 1.05– 1.26) per SD in 
this data set.
For fatty acids, higher proportions of saturated as 
well as monounsaturated fatty acids, relative to total 
fatty acids, were associated with increased risk for 
both PAD and CAD. Higher proportions of polyunsat-
urated fatty acids were associated with decreased 
risk for both PAD and CAD events. Glycolysis- related 
measures (glucose, lactate, pyruvate, and glycerol) as-
sociated with PAD risk, and 2 of these (glucose and 
lactate) had stronger associations with PAD risk than 
with CAD risk (Pheterogeneity<0.001). For amino acids, 
the strongest association for higher CAD and PAD risk 
was for alanine. Also, the aromatic amino acids (phe-
nylalanine and tyrosine) were robustly associated with 
higher risk for both CAD and PAD. Branched- chain 
amino acids had similar HRs as aromatic amino acids 
in the case of CAD risk, but for PAD the associations 
were slightly weaker and not statistically significant. 
Glutamine displayed an inverse association with PAD 
risk but was not significantly associated with CAD 
risk. The inflammation- related protein markers albumin 
and glycoprotein acetyls (GlycA) were associated with 
both end points. GlycA displayed the single strongest 
HR per SD change for both CAD (HR, 1.31; 95% CI, 
1.26– 1.37) and PAD (HR, 1.53; 95% CI, 1.42– 1.65) risk 
among all the metabolic biomarkers analyzed in this 
study.
Biomarker Signature for PAD Compared 
With CAD
The overall consistency and differences in the bio-
marker associations for PAD and CAD are illustrated 
in Figure 4. The consistency of the overall pattern of 
biomarker associations for the 2 end points was mod-
erate when comparing the HRs for the 57 highlighted 
biomarkers (R2=0.49). The plot reinforces 2 observa-
tions: First, LDL and HDL lipid biomarkers were ro-
bustly associated with future CAD but not strongly with 
PAD. Second, for biomarkers associated with both 
outcomes, the largest heterogeneity was observed for 
GlycA and glycolysis- related metabolites, which all had 
stronger associations with future PAD.
Complete Biomarker Associations and 
Sensitivity Analyses
Results for all 250 metabolic measures quantified 
by the Nightingale NMR metabolomics platform are 
Figure 3. Fatty acid, polar metabolite, and inflammatory protein associations with incident coronary artery disease (CAD) 
(2073 incident events; red) and peripheral artery disease (PAD) (498 incident events; dark blue).
Hazard ratios (HRs) and 95% CIs are shown per 1- SD higher biomarker concentration, with numerical results indicated on the right- 
hand side. Models are adjusted for sex and age. Open circles denote P≥0.0005, and closed circles denote P<0.0005. Asterisks denote 
P<0.001 for heterogeneity between PAD and CAD associations. BCAA indicates branched- chain amino acids; DHA, docosahexaenoic 
acid; LA, linoleic acid; MUFA, monounsaturated fatty acids; P- het, P value for heterogeneity; PUFA, polyunsaturated fatty acids; and 
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shown in Figure  S2. All numerical results are listed 
in Table S1. The findings in Figures 1 through 4 are 
presented as meta- analysis of the 5 prospective co-
horts; the results were consistent within individual 
cohorts for both CAD and PAD, despite large differ-
ences in follow- up time and fraction of individuals on 
lipid- lowering medication at baseline (Figures S3 and 
S4).
We further examined the influence of traditional 
cardiovascular risk factors on the biomarker asso-
ciations. The overall biomarker association profiles 
did not change substantially when further adjusting 
for systolic blood pressure, body mass index, diabe-
tes status, smoking, and lipid- lowering medication 
(Figure S5). In particular, the pronounced differences 
in CAD and PAD associations for apolipoprotein and 
cholesterol were similar. Many of the nontraditional 
biomarkers, such as omega- 6 fatty acids, glycoly-
sis metabolites, phenylalanine, albumin, and GlycA, 
remained significantly associated with future PAD 
events after adjusting for the traditional risk factors, 
including prevalent diabetes.
To examine if inclusion of diabetes with circula-
tory complications in the PAD event definition could 
partly underpin the observed biomarker differences, 
the performed sensitivity analyses were all diabe-
tes cases that were registered before incidence of 
PAD and CAD were excluded (Figure  S6). Some of 
the biomarker associations for PAD were attenuated 
in this sensitivity analysis (eg, glucose, alanine, and 
Figure 4. Consistency of metabolic biomarker associations for coronary artery disease (CAD) 
(2073 incident events; red) and peripheral artery disease (PAD) (498 incident events; dark blue).
The hazard ratio of each biomarker is given with 95% CIs in gray vertical and horizontal error bars. The 
red dashed line denotes the diagonal. Biomarkers with P<0.001 for heterogeneity between associations 
with PAD and CAD are marked by black color coding. Apo indicates apolipoprotein; C, cholesterol; GlycA, 
glycoprotein acetyls; HDL, high- density lipoprotein; IDL, intermediate- density lipoprotein; L, large; LA, 
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glutamine), whereas other biomarker associations 
with PAD, such as lactate, phenylalanine, and GlycA, 
remained similar. Furthermore, the differences in apo-
lipoprotein and lipid associations for CAD compared 
with PAD were similar.
DISCUSSION
Detailed lipoprotein and metabolite profiling in large 
population- based cohorts uncovered several novel 
circulating biomarkers reflecting future risk for PAD 
events. The overall biomarker association profile 
showed several molecular differences in comparison 
to biomarkers associated with future CAD events. 
We have 2 main findings: First, the most heterogene-
ous biomarker associations were for standard lipid 
measures, which were strongly associated with fu-
ture CAD events but not with the risk for PAD. This 
difference was particularly marked for apolipoprotein 
B and LDL cholesterol. Second, a broad range of 
emerging biomarkers, including triglycerides in LDL 
and HDL particles, circulating fatty acids, glycolysis 
metabolites, amino acids, and inflammatory protein 
markers, showed robust association with both end 
points; and in many cases, the HRs were stronger for 
PAD than for CAD. These findings exemplify the pos-
sibility for characterization of molecular similarities 
and differences of related cardiovascular diseases via 
large- scale metabolic profiling to enhance causative 
understanding and potentially help to point toward 
novel treatment opportunities.
The cause of atherosclerotic diseases in any arte-
rial bed has historically been considered equivalent, 
but recently, more detailed lipid and metabolic profil-
ing has revealed partly distinct association profiles for 
different atherosclerosis subtypes.7,12 With the aging 
of the global population and increasing prevalence of 
obesity and diabetes, it is likely that especially PAD 
will become more common in future.1 We identified 
several novel biomarkers for PAD, which could help to 
elucidate pathophysiological differences of PAD in re-
lation to other atherosclerotic diseases. For example, 
our findings suggest that standard lipid testing does 
not capture the risk for developing PAD. Similar over-
all conclusions were recently also suggested by Aday 
et al,12 based on standard and advanced lipid testing 
in the WHS. In contrast to Aday et al,12 however, we 
did not observe HDL cholesterol, apolipoprotein A1, or 
LDL particle concentrations to be associated with fu-
ture PAD events in our study. These deviating results 
might be explained by the differences in cohort char-
acteristics and subtle differences in PAD outcome 
definitions. Although the WHS only included female 
health care professionals, the participants of the pres-
ent study are representative of the general Finnish 
population. Furthermore, our PAD definition was 
wider compared with theirs, as it also included cases 
of diabetes with circulatory complications. However, 
in our sensitivity analyses that excluded all diabetes 
cases before PAD and CAD events, the prominent dif-
ferences in lipid associations for CAD compared with 
PAD were not altered. The overall pattern of biomarker 
associations was also distinct for the associations of 
these metabolic biomarkers previously reported for 
future diabetes risk20; for example, branched- chain 
amino acids are strongly associated with incident di-
abetes, but were not associated with incident PAD 
Table 1. Baseline Characteristics and Event Numbers in the 5 Cohorts
Variable FINRISK 1997 FINRISK 2002 FINRISK 2007 FINRISK 2012 Health 2000
No. of participants 7254 7575 5550 5231 6047
Women, N (%) 3678 (51) 4195 (55) 2939 (53) 2765 (53) 3317 (55)
Age, mean (SD), y 48 (13) 48 (13) 50 (14) 51 (14) 54 (15)
Body mass index, mean (SD), kg/m2 26.6 (4.5) 26.8 (4.7) 27.1 (4.8) 27.0 (4.9) 27.0 (4.6)
Systolic blood pressure, mean (SD), mm Hg 136 (20) 135 (20) 136 (20) 134 (19) 135 (21)
Total cholesterol, mean (SD), mmol/L 5.5 (1.1) 5.6 (1.1) 5.3 (1.0) 5.3 (1.0) 6.0 (1.1)
HDL cholesterol, mean (SD), mmol/L 1.4 (0.4) 1.5 (0.4) 1.4 (0.4) 1.5 (0.4) 1.4 (0.4)
Triglycerides, mean (SD), mmol/L 1.5 (1.0) 1.4 (0.9) 1.4 (0.9) 1.4 (0.9) 1.6 (1.0)
Lipid- lowering medication, N (%) 184 (2.5) 416 (5.5) 664 (12) 683 (13) 342 (5.7)
Antihypertensive medication, N (%) 915 (13) 1022 (13) 1064 (19) 1081 (21) 962 (16)
Current smoking, N (%) 1719 (24) 1948 (26) 1159 (21) 997 (19) 1264 (21)
Prevalent diabetes, N (%) 415 (6) 393 (5) 439 (8) 582 (11) 274 (5)
Incident CAD, N (%) 752 (10) 435 (6) 228 (4) 81 (2) 577 (10)
Incident PAD, N (%) 190 (3) 99 (1) 70 (1) 16 (0) 123 (2)
Follow- up time, median, y 18.8 13.8 8.9 3.9 15.3
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in this study. As an additional novelty, we identified 
several nonlipid biomarkers to be strongly associated 
with future PAD events. Many of these novel biomark-
ers for PAD risk, including fatty acid measures and 
biomarkers related to glycolysis and inflammation, re-
mained associated in the sensitivity analysis excluding 
all diabetes cases before PAD and CAD events.
In addition to the causative insights, there are also 
potential clinical implications of our results. First, our 
findings of novel metabolic biomarkers could guide 
the development of preventative therapies. These 
results reinforce the importance of focusing beyond 
LDL cholesterol levels for assessing PAD risk,12 and 
we extend this message to suggest a focus also 
beyond small LDL particle numbers and HDL lip-
ids. Ongoing trials are testing novel treatments for 
triglyceride- rich lipoproteins and atherogenic dyslip-
idemia more widely and may hold potential to improve 
many of the triglyceride and fatty acid composition 
biomarkers herein shown to associate robustly with 
incident PAD. However, we emphasize that our find-
ings are of observational nature, meaning we cannot 
make deductions on causation. Mendelian random-
ization analyses may eventually help to provide fur-
ther information on the causative roles of fatty acids 
and triglyceride- related pathways in PAD.22 Second, 
although we concluded that standard lipid testing 
is unlikely to be adequate in PAD risk prediction, we 
identified novel risk factors for PAD that could poten-
tially improve risk prediction. However, the additive 
predictive value of these biomarkers was not tested in 
the present study and needs to be evaluated in large 
independent data sets.
Our study has strengths and limitations. Strengths 
include large sample size, spanning 5 prospective co-
horts. This enabled analyses of incident symptomatic 
PAD and CAD with a high number of events, obtained 
from nationwide registries with close to complete cov-
erage of inpatient diagnoses.13– 16 We used a widely 
used high- throughput metabolomics platform that 
has received regulatory approvals for diagnostics use. 
The biomarker associations were consistent across 
the cohorts, despite differences in follow- up time and 
use of lipid- lowering medication. Furthermore, the 
correlations between the routine lipids measured by 
clinical chemistry assays from fresh samples and by 
NMR 6 to 15 years after sample collection were high. 
The findings should be interpreted in the context of 
limitations of this study. First, our PAD diagnosis was 
based on hospitalized PAD events and, thus, does 
not cover milder forms of PAD. Second, because of 
observational study settings, causal conclusions can-
not be made. However, these results demonstrate the 
potential of more accurate lipoprotein and metabolic 
profiling and call for additional studies to evaluate cau-
sality of these biomarkers. Third, although the samples 
were only semifasting in this study (median, 5 hours), 
we have previously shown that the analyzed panel of 
NMR- based biomarkers has highly similar associations 
with incident cardiovascular events for nonfasting and 
fasting samples.23 Finally, this study was conducted 
in Finnish population cohorts only. Large prospective 
studies in other populations are needed to evaluate 
generalizability and ethnic differences in the biomarker 
associations.
In conclusion, metabolic profiling of large pro-
spective cohorts highlights prominent differences 
in the biomarker profile associated with future PAD 
events compared with CAD events. Although routine 
cholesterol and apolipoprotein measures were not 
robustly associated with the risk for PAD, metabolic 
biomarkers reflecting triglyceride metabolism, fatty 
acid balance, glycolysis, and chronic inflammation 
were stronger associated with future PAD events than 
with CAD event. This may suggest that the drivers for 
atherosclerosis processes are partly distinct in pe-
ripheral compared with coronary arteries; however, 
further studies are needed to determine whether 
these findings represent meaningful and clinically 
actionable pathophysiological differences. Our re-
sults highlight the need to look beyond atherogenic 
dyslipidemia for identification of patients at high risk 
for PAD while still in asymptomatic stages, and for 
informing development of preventative options and 
pharmacological treatments for this increasingly 
prevalent disease.
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Table S1. Numerical list of associations between all 250 metabolic biomarkers and 
incident PAD and CAD, in SD-scaled units and absolute concentrations (see Excel file). 
Sheet 1 shows biomarkers associations using models adjusted for sex and age. 
Sheet 2 shows biomarker associations between using models adjusted for sex, age, 
smoking, systolic blood pressure, blood pressure treatment, prevalent diabetes, body mass 
index and lipid-lowering medication. 
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Figure S1. Scatter plots and correlations between biomarkers measured by both NMR and 
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Routine lipids and apolipoprotein measures were measured by the Nightingale NMR platform and 
clinical chemistry analyzers in all five cohorts (n~31 500). Glucose, creatinine and albumin were only 
measured in a few cohorts by clinical chemistry. The slope and offset of the linear fit are indicated. R 
denotes Pearson’s correlation coefficients. All units are mmol/L except for apolipoproteins and 
albumin, which are g/l. Clinical chemistry measurements were conducted in a central laboratory 
from frozen serum samples soon after each of the cohort surveys. Nightingale NMR was measured 
from frozen serum samples (350µL aliquots) during 2018-19, with the exception of FINRISK 1997 
samples which were measured in 2012. Samples with shorter storage time show the best 
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Figure S2. Associations for all 250 metabolic biomarkers with incident CAD (2073 events) 
and incident PAD (498 events). 
Hazard ratios with incident CAD (red) and PAD (black) per SD higher concentration. Models are adjusted for 
sex and age is used as timescale. Results were meta-analyzed for 31 657 individuals from the five prospective 
cohorts. Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for heterogeneity 
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Hazard ratios with incident CAD (red) and PAD (black) per SD higher concentration. Models are adjusted for 
sex and age is used as timescale. Results were meta-analyzed for 31 657 individuals from the five prospective 
cohorts. Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for heterogeneity 
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Hazard ratios with incident CAD (red) and PAD (black) per SD higher concentration. Models are adjusted for 
sex and age is used as timescale. Results were meta-analyzed for 31 657 individuals from the five prospective 
cohorts. Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for heterogeneity 
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Figure S3. Associations for all 250 metabolic biomarkers with incident PAD (498 events) in 
each cohort separately. 
Hazard ratios for incident PAD per SD higher concentration. Models are adjusted for sex and age is used as 
timescale. Results are shown for each cohort separately and meta-analyzed for 31 657 individuals from the 
five cohorts (black dots). The confidence intervals are much wider in the FINRISK 2012 cohort since the 
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Hazard ratios for incident PAD per SD higher concentration. Models are adjusted for sex and age is used as 
timescale. Results are shown for each cohort separately and meta-analyzed for 31 657 individuals from the 
five cohorts (black dots). The confidence intervals are much wider in the FINRISK 2012 cohort since the 
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Hazard ratios for incident PAD per SD higher concentration. Models are adjusted for sex and age is used as 
timescale. Results are shown for each cohort separately and meta-analyzed for 31 657 individuals from the 
five cohorts (black dots). The confidence intervals are much wider in the FINRISK 2012 cohort since the 
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Figure S4. Associations for all 250 metabolic biomarkers with incident CAD (2073 events) 
in each cohort separately. 
Hazard ratios for incident CAD per SD higher concentration. Models are adjusted for sex and age is used as 
timescale. Results are shown for each cohort separately and meta-analyzed for 31 657 individuals from the 
five cohorts (black dots). The confidence intervals are much wider in the FINRISK 2012 cohort since the 
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Hazard ratios for incident CAD per SD higher concentration. Models are adjusted for sex and age is used as 
timescale. Results are shown for each cohort separately and meta-analyzed for 31 657 individuals from the 
five cohorts (black dots). The confidence intervals are much wider in the FINRISK 2012 cohort since the 
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Hazard ratios for incident CAD per SD higher concentration. Models are adjusted for sex and age is used as 
timescale. Results are shown for each cohort separately and meta-analyzed for 31 657 individuals from the 
five cohorts (black dots). The confidence intervals are much wider in the FINRISK 2012 cohort since the 
number of events if very modest here due to short follow-up time. 
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Figure S5. Associations for all 250 metabolic biomarkers with incident CAD (2034 events) and 
incident PAD (489 events) with additional adjustment for smoking, systolic blood pressure, 
blood pressure treatment, prevalent diabetes, BMI and lipid-lowering medication. 
Hazard ratios with incident CAD (red) and PAD (black) per SD higher concentration. Models are adjusted for 
sex, age (as timescale), smoking, systolic blood pressure, blood pressure treatment, prevalent diabetes, body 
mass index and lipid-lowering medication. Results are meta-analyzed for 31 376 individuals from five 
prospective cohorts. Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for 
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Hazard ratios with incident CAD (red) and PAD (black) per SD higher concentration. Models are adjusted for 
sex, age (as timescale), smoking, systolic blood pressure, blood pressure treatment, prevalent diabetes, body 
mass index and lipid-lowering medication. Results are meta-analyzed for 31 376 individuals from five 
prospective cohorts. Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for 
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Hazard ratios with incident CAD (red) and PAD (black) per SD higher concentration. Models are adjusted for 
sex, age (as timescale), smoking, systolic blood pressure, blood pressure treatment, prevalent diabetes, body 
mass index and lipid-lowering medication. Results are meta-analyzed for 31 376 individuals from five 
prospective cohorts. Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for 
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Figure S6. Associations for all 250 metabolic biomarkers with incident CAD (1602 events) and 
incident PAD (329 events) when excluding all diabetes cases that occurred before PAD and CAD 
events. 
Hazard ratios with incident PAD (red) and CAD (black) per SD higher concentration. Models were adjusted for 
sex and age is used as timescale. All individuals who had diabetes at time of blood sampling, or developed 
diabetes (according to nationwide hospital and medical reimbursement registries) prior to PAD and CAD 
events were excluded. Results are meta-analyzed for 31 484 individuals from the five prospective cohorts. 
Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for heterogeneity 
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Hazard ratios with incident PAD (red) and CAD (black) per SD higher concentration. Models were adjusted for 
sex and age is used as timescale. All individuals who had diabetes at time of blood sampling, or developed 
diabetes (according to nationwide hospital and medical reimbursement registries) prior to PAD and CAD 
events were excluded. Results are meta-analyzed for 31 484 individuals from the five prospective cohorts. 
Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for heterogeneity 
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Hazard ratios with incident PAD (red) and CAD (black) per SD higher concentration. Models were adjusted for 
sex and age is used as timescale. All individuals who had diabetes at time of blood sampling, or developed 
diabetes (according to nationwide hospital and medical reimbursement registries) prior to PAD and CAD 
events were excluded. Results are meta-analyzed for 31 484 individuals from the five prospective cohorts. 
Open circles denote P ≥ 0.0005, closed circles P < 0.0005. Asterisks denote P < 0.001 for heterogeneity 
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